Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lung Neoplasms 26Prostatic Neoplasms 24Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Multiple Myeloma 14Sarcoma 12Leukemia, Myeloid, Acute 12Glioma 12Lymphoma, Non-Hodgkin 10Carcinoma, Hepatocellular 10Wilms Tumor 9Osteosarcoma 9Colorectal Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Rhabdomyosarcoma 7Rhabdoid Tumor 7Mouth Neoplasms 7Melanoma 7Medulloblastoma 7Hepatoblastoma 7Neuroectodermal Tumors, Primitive, Peripheral 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Head and Neck Neoplasms 6

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 34Whole-Body Irradiation 33Bortezomib 33ibrutinib 29Dexamethasone 27Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 22Melphalan 20Filgrastim 20zanubrutinib 18Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Flow Cytometry 10Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Indium 9Cyclosporins 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × X-Rays × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡